246 related articles for article (PubMed ID: 32581595)
1. Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Xie N; Qin T; Ren W; Yao H; Yu Y; Hong H
Cancer Manag Res; 2020; 12():4241-4250. PubMed ID: 32581595
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
3. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
4. A Gene Panel Associated With Abemaciclib Utility in
Brett JO; Dubash TD; Johnson GN; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Lloyd MR; Kambadakone A; Spring LM; Micalizzi DS; Onozato ML; Che D; Nayar U; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Han HS; Iafrate AJ; Ryan LY; Juric D; Moy B; Ellisen LW; Maheswaran S; Wagle N; Haber DA; Bardia A; Wander SA
JCO Precis Oncol; 2023 May; 7():e2200532. PubMed ID: 37141550
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of palbociclib plus endocrine therapy for patients with HR
Zhong B; Zhang J; Wu J; Sun L; Li S; Zeng X; Gan L
Ann Transl Med; 2022 Mar; 10(6):362. PubMed ID: 35434007
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
Dai Q; Wang Y; Liao M; Chen H
Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
[TBL] [Abstract][Full Text] [Related]
8. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
[TBL] [Abstract][Full Text] [Related]
9. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
Liu Y; Wu J; Ji Z; Chen L; Zou J; Zheng J; Lin W; Cai J; Chen Y; Zheng D; Chen Y; Li Z
BMC Cancer; 2023 Aug; 23(1):816. PubMed ID: 37653504
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole
Jhaveri K; O'Shaughnessy J; Fasching PA; Tolaney SM; Yardley DA; Sharma VK; Biswas C; Thuerigen A; Pathak P; Rugo HS
Ther Adv Med Oncol; 2023; 15():17588359231216095. PubMed ID: 38107828
[TBL] [Abstract][Full Text] [Related]
12. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study.
Zhang QY; Sun T; Yin YM; Li HP; Yan M; Tong ZS; Oppermann CP; Liu YP; Costa R; Li M; Cheng Y; Ouyang QC; Chen X; Liao N; Wu XH; Wang XJ; Feng JF; Hegg R; Kanakasetty GB; Coccia-Portugal MA; Han RB; Lu Y; Chi HD; Jiang ZF; Hu XC
Ther Adv Med Oncol; 2020; 12():1758835920963925. PubMed ID: 33149768
[TBL] [Abstract][Full Text] [Related]
13. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR
Yuan Y; Zhang S; Wang T; Wang B; Wang S; Shi J; Sun T; Yin Y; Ouyang Q; Li J; Wen Y; Zhang L; Jiang Z
Transl Breast Cancer Res; 2023; 4():10. PubMed ID: 38751483
[TBL] [Abstract][Full Text] [Related]
15. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
[TBL] [Abstract][Full Text] [Related]
16. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
18. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz MP; Toi M; Huober J; Sohn J; Trédan O; Park IH; Campone M; Chen SC; Manso LM; Paluch-Shimon S; Freedman OC; O'Shaughnessy J; Pivot X; Tolaney SM; Hurvitz S; Llombart-Cussac A; André V; Saha A; van Hal G; Shahir A; Iwata H; Johnston SRD
Ann Oncol; 2024 May; ():. PubMed ID: 38729566
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
